Serum YKL-40 following resection for cerebral glioblastoma
about
Circulating glioma biomarkersUnveiling YKL-40, from Serum Marker to Target Therapy in GlioblastomaFrom the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity.Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.Transcriptome sequencing of neurologic diseases associated genes in HHV-6A infected human astrocyte.Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.Circulating biomarkers of CNS tumors: an update.Molecular prognostic factors in glioblastoma: state of the art and future challenges.Liquid biopsies in patients with diffuse glioma.Emerging circulating biomarkers in glioblastoma: promises and challenges.Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.Neuro-oncology: a step towards clinical blood biomarkers of glioblastoma.Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
P2860
Q26830329-1E856771-6CDC-454D-8478-995316E23012Q26998561-E84EA787-8613-4E54-A763-ABAE8767F6A9Q35828508-BF576D30-C6E8-4B3D-B08F-0C35AB95ACF2Q36545468-0D76B96D-2405-4BA8-B8E3-3DD4CD034ED2Q37191560-3EE6660E-8A81-4D3A-B590-D3BAC2943509Q37565386-5FE4A61B-38B9-4E5F-AB54-1D3A618943D8Q37733730-EA092094-3885-4439-AD42-707B921E309CQ38095109-EF1BBB26-4026-44DE-972B-EF836E0912CEQ38233134-79472D59-C541-4F64-8049-4C17CBB06118Q38365590-E93BE161-1EC4-4240-8631-85D4CB5B09CFQ38591062-A596115C-184A-4858-99A9-9522B5556E6BQ38811271-984DF2CE-6297-4FDA-B517-93C51CE406E5Q48467746-5A8FD786-FD1F-4F00-86EE-F527268B0072Q48595349-0F832E95-8018-4E83-BDD6-8A1A6001F5CCQ50293199-F49B470D-942C-41D2-8D34-3805CBB400C3Q53204820-3AF8244F-126F-4702-8D63-32DEFDCE3A2D
P2860
Serum YKL-40 following resection for cerebral glioblastoma
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Serum YKL-40 following resection for cerebral glioblastoma
@ast
Serum YKL-40 following resection for cerebral glioblastoma
@en
Serum YKL-40 following resection for cerebral glioblastoma
@nl
type
label
Serum YKL-40 following resection for cerebral glioblastoma
@ast
Serum YKL-40 following resection for cerebral glioblastoma
@en
Serum YKL-40 following resection for cerebral glioblastoma
@nl
prefLabel
Serum YKL-40 following resection for cerebral glioblastoma
@ast
Serum YKL-40 following resection for cerebral glioblastoma
@en
Serum YKL-40 following resection for cerebral glioblastoma
@nl
P2093
P2860
P3181
P1476
Serum YKL-40 following resection for cerebral glioblastoma
@en
P2093
Alessandro Della Puppa
Andrea Ballin
Andrea Padoan
Daniela Bernardi
Mariateresa Sartori
Mario Plebani
Renato Scienza
Renzo Manara
P2860
P2888
P304
P3181
P356
10.1007/S11060-011-0762-7
P407
P577
2012-04-01T00:00:00Z
P6179
1038605004